Items per page
Sort by

Send to:

Choose Destination

Results: 8

Cited In for PubMed (Select 20063399)


Is the risk of motor neuron disease increased or decreased after cancer? An Australian case-control study.

Stoyanov A, Pamphlett R.

PLoS One. 2014 Jul 24;9(7):e103572. doi: 10.1371/journal.pone.0103572. eCollection 2014.


Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses.

Ibáñez K, Boullosa C, Tabarés-Seisdedos R, Baudot A, Valencia A.

PLoS Genet. 2014 Feb 20;10(2):e1004173. doi: 10.1371/journal.pgen.1004173. eCollection 2014 Feb.


Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease.

Dong J, Gao J, Nalls M, Gao X, Huang X, Han J, Singleton AB, Chen H; International Parkinson's Disease Genomics Consortium (IPDGC).

Neurobiol Aging. 2014 Jun;35(6):1512.e5-10. doi: 10.1016/j.neurobiolaging.2013.12.020. Epub 2013 Dec 27.


The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells.

Pan T, Zhu J, Hwu WJ, Jankovic J.

PLoS One. 2012;7(9):e45183. doi: 10.1371/journal.pone.0045183. Epub 2012 Sep 19.


An automated framework for hypotheses generation using literature.

Abedi V, Zand R, Yeasin M, Faisal FE.

BioData Min. 2012 Aug 29;5(1):13. doi: 10.1186/1756-0381-5-13.


Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.

Liu DZ, Ander BP.

ScientificWorldJournal. 2012;2012:491737. doi: 10.1100/2012/491737. Epub 2012 Apr 1. Review.


Meta-analysis of the relationship between Parkinson disease and melanoma.

Liu R, Gao X, Lu Y, Chen H.

Neurology. 2011 Jun 7;76(23):2002-9. doi: 10.1212/WNL.0b013e31821e554e. Review.


The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Falk T, Gonzalez RT, Sherman SJ.

Int J Mol Sci. 2010 Aug 5;11(8):2875-900. doi: 10.3390/ijms11082875. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk